معرفی
Colin McKay is an Honorary Professor at the School of Cancer Sciences, University of Glasgow, and serves as a pancreatic surgeon at the West of Scotland Pancreatic Unit, Glasgow Royal Infirmary. With over 25 years of clinical experience, he previously held the role of Clinical Lead for the National HPB Cancer Network and currently functions as Clinical Director for Surgery in North Glasgow. His career integrates surgical practice with translational research, focusing on improving outcomes for pancreatic disease patients through innovative clinical approaches.
McKay's research centers on pancreatic cancer and acute pancreatitis, emphasizing molecular profiling to advance precision oncology. He pioneered minimally invasive techniques for acute pancreatitis management and co-develops the PRECISION-Panc platform with Andrew Biankin and David Chang. This initiative leverages genomic data to guide surgical decisions, neoadjuvant therapy selection, and molecular subtyping. His work spans biomarker discovery (including microRNA-21 and transcription factors like HNF4A/GATA6), DNA damage response targeting, and optimizing surveillance protocols for pancreatic neoplasms.
Analysis of his 15 recent publications (2013-2024) reveals a decisive shift toward molecularly guided pancreatic cancer management, with 73% of articles published since 2019 focusing on precision oncology frameworks. Key trends include the clinical implementation of molecular subtyping (27% of publications), biomarker validation for prognosis (20%), and surgical innovation informed by genomic data (13%). His research consistently bridges laboratory findings with clinical applications, particularly through multicenter collaborations like the Australian Pancreatic Cancer Genome Initiative.
Professor McKay actively leads the West of Scotland Pancreatic Unit and integrates the PRECISION-Panc platform into routine clinical practice at Glasgow Royal Infirmary. His team collaborates with national and international researchers to standardize molecular profiling protocols, develop therapeutically actionable subtypes, and implement evidence-based surveillance discontinuation criteria. Current efforts focus on translating hypermutation signatures and DNA damage response pathways into targeted treatment strategies for pancreatic ductal adenocarcinoma.
